Mogens Winkel Madsen
Profile
Mogens Winkel Madsen worked as the Chief Scientific Officer at LiPlasome Pharma A.
Former positions of Mogens Winkel Madsen
Companies | Position | End |
---|---|---|
LiPlasome Pharma A/S
LiPlasome Pharma A/S Pharmaceuticals: MajorHealth Technology LiPlasome Pharma A/S develops, produces and supplies drugs for chemotherapy treatment. It has developed a technology based on incapsulation of chemotherapy in liposomes (fatty molecules) that will only dissolve in and around cancer tissue (tumors or metastases). The firm’s technology will improve chemotherapy treatment within a wide range of cancer diseases significantly as it improves the balance between effect and side effects. LiPlasome’s first drug candicate LiplaCis which is a liposonal formulation of Cisplatin, is in clinical phase 1. The company was founded in January 2001 by Ole Gunner Mouritsen and is headquartered in Hoersholm, Denmark. | Chief Operating Officer | - |
Experiences
Positions held
Linked companies
Private companies | 1 |
---|---|
LiPlasome Pharma A/S
LiPlasome Pharma A/S Pharmaceuticals: MajorHealth Technology LiPlasome Pharma A/S develops, produces and supplies drugs for chemotherapy treatment. It has developed a technology based on incapsulation of chemotherapy in liposomes (fatty molecules) that will only dissolve in and around cancer tissue (tumors or metastases). The firm’s technology will improve chemotherapy treatment within a wide range of cancer diseases significantly as it improves the balance between effect and side effects. LiPlasome’s first drug candicate LiplaCis which is a liposonal formulation of Cisplatin, is in clinical phase 1. The company was founded in January 2001 by Ole Gunner Mouritsen and is headquartered in Hoersholm, Denmark. | Health Technology |
- Stock Market
- Insiders
- Mogens Winkel Madsen